Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)

• Bruce K. Patterson,
• Ram Yogendra,
• Jose Guevara-Coto,
• Rodrigo A. Mora-Rodriguez,
• Eric Osgood,
• John Bream,
• Purvi Parikh,
• Mark Kreimer,
• Devon Jeffers,
• Cedric Rutland,
• Gary Kaplan,
• Michael Zgoda

Affiliations

Bruce K. Patterson

IncellDX Inc., San Carlos, CA, United States

Ram Yogendra

Department of Anesthesiology, Beth Israel Lahey Health, Burlington, MA, United States

Jose Guevara-Coto

Centro de Investigación en Cirugía y Cáncer (CICICA), Universidad de Costa Rica, San Jose, Costa Rica

Rodrigo A. Mora-Rodriguez

Lab of Tumor Chemosensitivity, CIET/DC Lab, Faculty of Microbiology, Universidad de Costa Rica, San Jose, Costa Rica

Eric Osgood

Department of Medicine, St. Francis Medical Center, Trenton, NJ, United States

John Bream

Department of Emergency Medicine, Novant Health Kernersville Medical Center, Kernersville, NC, United States

Purvi Parikh

Department of Allergy and Immunology, NYU Langone Tisch Hospital, New York, NY, United States

Mark Kreimer

Department of Emergency Medicine, New York Presbyterian Hospital, Brooklyn, NY, United States

Devon Jeffers

Department of Anesthesiology, Stamford Hospital, Stamford, CT, United States

Cedric Rutland

0Rutland Medical Group, Newport Beach, CA, United States

Gary Kaplan

1Department of Community and Family Medicine, Georgetown University Medical Center, Washington, DC, United States

Michael Zgoda

2Department of Medicine, Creighton University School of Medicine, Phoenix, AZ, United States